Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haoxi Health Technology (HAO) Total Current Liabilities (2023 - 2025)

Haoxi Health Technology's Total Current Liabilities history spans 3 years, with the latest figure at $4.4 million for Q4 2025.

  • Quarterly Total Current Liabilities rose 34.76% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, up 34.76% year-over-year, with the annual reading at $3.9 million for FY2025, 0.48% changed from the prior year.
  • Total Current Liabilities came in at $4.4 million for Q4 2025, up from $3.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $4.4 million in Q4 2025 to a low of $2.6 million in Q2 2023.
  • The 3-year median for Total Current Liabilities is $3.9 million (2024), against an average of $3.6 million.
  • Year-over-year, Total Current Liabilities surged 50.07% in 2024 and then rose 0.48% in 2025.
  • Haoxi Health Technology's Total Current Liabilities stood at $2.6 million in 2023, then grew by 27.82% to $3.3 million in 2024, then surged by 34.76% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for HAO's Total Current Liabilities are $4.4 million (Q4 2025), $3.9 million (Q2 2025), and $3.3 million (Q4 2024).